title: The effect of fosfosal and acetylsalicylic acid on leukocyte migration and PGE2 concentration in experimentally induced acute inflammation.
abstract: The effect of fosfosal, a non-acetylated salicylic acid derivative, on the content of prostaglandin E2 (PGE2) and the migration of polymorphonuclear leukocytes in inflammatory exudates induced by s.c. implantation of 0.5% carrageenan soaked sponges in rats has been determined. Fosfosal, which does not inhibit PG synthesis in vitro, is capable of reducing, in a dose-dependent manner, the PGE2 content of the exudates, with a maximum reduction of 50-60% at a total dose of 100 mg/kg i.p. Acetylsalicylic acid was slightly more potent (68% reduction, 2 x 50 mg/kg i.p.). Six hours after fosfosal administration, salicylic acid, the principal metabolite of fosfosal, accumulated in the exudates at concentrations of about 100 micrograms/ml. These concentrations were sufficient to inhibit PG synthetase activity in vitro. Neither fosfosal nor acetylsalicyclic acid affected polymorphonuclear leukocyte migration at doses which significantly reduced the concentrations of PGE2. Indomethacin, used as reference, reduced leukocyte migration by 28 and 45% at a dose of 1 and 10 mg/kg i.p. respectively. The results indicate that fosfosal, in spite of its lack of effect on PG biosynthesis in vitro, exerts an effect on the inflammatory locus in vivo which may account, at least in part, for its anti-inflammatory activity. Moreover, our results confirm that the inhibition of PG synthesis and leukocyte migration are mediated by different mechanisms.
authors.affiliation: Department of Pharmacology, Research Center of J. Uriach & Cia. S.A., Barcelona, Spain.
authors.forename: L A
authors.initials: LA
authors.lastname: Gómez
authors.forename: J
authors.initials: J
authors.lastname: Ramis
authors.forename: J
authors.initials: J
authors.lastname: Julve
authors.forename: J
authors.initials: J
authors.lastname: García-Rafanell
authors.forename: J
authors.initials: J
authors.lastname: Forn
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D002464:Cell Migration Inhibition; D015232:Dinoprostone; D007213:Indomethacin / Q000494:pharmacology; D007249:Inflammation / Q000276:immunology / Q000378:metabolism*; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D010755:Organophosphates / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D011458:Prostaglandins E / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010755:Organophosphates; D009943:Organophosphorus Compounds; D011458:Prostaglandins E; C000380:fosfosal; D015232:Dinoprostone; D001241:Aspirin; D007213:Indomethacin